Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, containing a complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention relates to compounds of [Formula A]: including N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide, 2-((9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)carbamoyl)phenyl acetate, methods for preparing the compounds, and compositions including the compounds as active ingredients. The compounds of the present invention are very effective in anti-inflammation and pain relief. The compositions of the present invention are effective in preventing or treating inflammation and/or pain.

Abstract: The present invention relates to N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepine-3-yl)-2-hydroxybenzamide, 2((9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepine-3-yl)carbamoyl)phenyl acetate, methods for preparing the compounds, and compositions including the compounds as active ingredients. The compounds of the present invention are very effective in anti-inflammation and pain relief. The compositions of the present invention are effective in preventing or treating inflammation and/or pain.

Abstract: The present invention relates to a method for increasing the binding reversibility of a ?-conotoxin to a N-type calcium channel, which comprises preparing a ?-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and 3) of the ?-conotoxin represented by the formula I, such that the prepared ?-conotoxin has the increased binding reversibility to N-type calcium channel. In addition, the present invention relates to a novel ?-conotoxin and a pharmaceutical composition having plausible properties in view of blocking activity to and specificity to N-type calcium channel, and dramatically improved binding reversibility to N-type calcium channel.

Abstract: The present invention relates to a method for increasing the binding reversibility of a ?-conotoxin to a N-type calcium channel, which comprises preparing a ?-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and 3) of the ?-conotoxin represented by the formula I, such that the prepared ?-conotoxin has the increased binding reversibility to N-type calcium channel. In addition, the present invention relates to a novel ?-conotoxin and a pharmaceutical composition having plausible properties in view of blocking activity to and specificity to N-type calcium channel, and dramatically improved binding reversibility to N-type calcium channel.

Abstract: The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

Abstract: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH?CHCOOH or formula (a).

Abstract: The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according hours after CLP according to the present invention and pharmaceutical or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

Abstract: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH?CHCOOH or formula (a).

Abstract: Provided is a pharmaceutical composition which can effectively prevent and treat sepsis and stroke. The composition comprises lysophosphatidic acid or a pharmaceutically acceptable salt thereof as an effective ingredient.

Abstract: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH═CHCOOH or formula (a).